NCT01711463已完成1 期
A Randomized, Double-blind, Placebo-controlled, Four-way Crossover Study to Evaluate and Compare the Pharmacodynamics and Pharmacokinetics of Fluticasone Furoate /Vilanterol in Different Dose Combination (50/25mcg, 100/25mcg and 200/25mcg) After Single and Repeat Dose Administration From a Novel Dry Powder Device in Healthy Chinese Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- Systemic steroid PD effects
研究概览
简要总结
In this study, fluticasone furoate (FF) and vilanterol (VI) in different dose combinations (50/25mcg, 100/25mcg and 200/25mcg) will be administered from a single dry powder device to evaluate the PD, PK, safety and tolerability of the combination in healthy Chinese subjects. The information gathered will be used as a support of the clinical development program of the fixed dose combination of FF/VI inhalation powder in Chinese population.
详细描述
This is a single centre, double-blind, placebo-controlled, four-way cross over, randomized, single and repeat dose study. A total of 16 healthy subjects aged 18-45 years will be randomised with the aim of achieving at least 10 evaluable subjects to each treatment period. The primary objective is to evaluate the systemic steroid PD effects (serum cortisol 24 hour weighted mean on Day 7) of FF and systemic ß-adrenergic PD effects (ECG maximum QTcF 0-4h and whole blood potassium 0-4h in Day 1 and Day 7) of VI; the secondary objectives are aimed to evaluate the PK, safety and tolerability of FF/VI inhalation powder after a single and repeat dose administration.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •AST, ALT, alkaline phosphatase and bilirubin <= 1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
- •Healthy male or female between 18 and 45 years of age inclusive.
- •Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GSK Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures. Subjects with blood pressure values outside the normal range [systolic (90-139 mmHg) and diastolic (50-89 mmHg)] and subjects with ECG findings suggestive of a previous MI should always be excluded from enrollment.
- •A female subject is eligible to participate if she is of:
- •Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 MlU/ml and estradiol < 40 pg/ml (<147 pmol/L) is confirmatory].
- •Child-bearing potential and agrees to use one of the contraception methods listed in Section 8.1 for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception until completion of the follow-up visit.
- •Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods listed in Section 8.
- •This criterion must be followed from the time of the first dose of study medication until completion of the follow-up visit.
- •Body weight >= 50 kg and BMI within the range 19 - 24 kg/m2 (inclusive).
- •Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
- •No significant abnormality on 12-lead ECG at screening, including the following specific requirements:
- •Ventricular rate >= 45 beats per minute; PR interval <=210msec; No pathological Q waves; QRS interval to be >= 60msec and <=120msec; The waveforms must enable the QT interval to be clearly defined; QTc interval must be < 450msec (QTcF; machine or manual reading) based on a single ECG value, or an average from three ECGs obtained over a brief recording period.
- •Subjects who are current non-smokers, who have not used any tobacco products in the 12 month period preceding the screening visit, and have a pack history of <=5 pack years.
- •Subjects who are able to use the inhalation device satisfactorily.
排除标准
- •A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening
- •Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- •A positive pre-study drug/alcohol screen or on admission to the Unit.
- •A positive urinary cotinine test at screening or on admission to the Unit.
- •A positive test for HIV antibody.
- •History of regular alcohol consumption within 6 months of the study defined as: an average weekly intake of greater than 21 units or an average daily intake of greater than 3 units (males) or defined as an average weekly intake of greater than 14 units or an average daily intake of greater than 2 units (females). One unit is equivalent to a 285mL glass of full strength beer or 425mL schooner of light beer or 1 (30mL) measure of spirits or 1 glass (100mL) of wine (NHMRC Guidelines [NHMRC, 2001]).
- •The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- •Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- •Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
- •History of sensitivity to any of the study medications, or components (magnesium stearate and lactose etc.) or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
- •History of milk protein allergy.
- •History of any adverse reaction including immediate or delayed hypersensitivity to any ICS, β2-agonist or sympathomimetic drug.
- •Blood donation or sampled as a study subject within three months preceding the first dose of study drug and blood donation during the entire study.
- •Pregnant females as determined by positive urine pregnancy test at screening or prior to dosing.
- •Lactating females.
- •Subjects who have suffered an upper or lower respiratory tract infection within 4 weeks of the screening visit.
- •The subject has taken oral corticosteroids less than 8 weeks before the screening visit.
- •The subject has taken inhaled, intranasal or topical steroids less than 4 weeks before the screening visit.
- •Unwillingness or inability to follow the procedures outlined in the protocol.
- •Subject is mentally or legally incapacitated.
研究组 & 干预措施
FF/VI
Experimental
50/25 mcg, 100/25 mcg or 200/25 mcg
干预措施: Fluticasone Furoate/Vilanterol (Drug)
Placebo
Placebo Comparator
matching placebo
干预措施: Placebo (Drug)
结局指标
主要结局
Systemic steroid PD effects
时间窗: Day 7
Serum cortisol
Systemic ß-adrenergic PD effects
时间窗: Day 1 and Day 7
Maximum QTcF 0-4h and whole blood potassium
次要结局
- Plasma concentrations and derived PK parameters for FF/VI(Pre-dose, 5 min, 15 min, 30 min, 1h, 1.5h, 2h, 4h post dose on Day 1 and pre-dose, 5 min, 15 min, 30 min, 1h, 1.5h, 2h, 4h, 6h, 8h, 12h and 24h post dose on Day 7 and 8.)
- Vital signs(Screening Visit, Day 1, Day 7 and Follow-up Visit)
- 12-lead ECG(Screening Visit, Day 1, Day 7 and Follow-up Visit)
- Laboratory tests(Screening Visit, Day 8 of treatment period 4 or early withdrawal Visit and/or follow-up Visit)
- Adverse events(From the start of dosing with investigational product and until the follow-up visit.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and AdolescentsAsthmaNCT01147848GlaxoSmithKline810
撤回
4 期
The Efficacy of Fluticasone Furoate/Vilanterol Versus (vs) Fluticasone Furoate on AsthmaAsthmaNCT03363191GlaxoSmithKline
已完成
3 期
Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent AsthmaticsAsthmaNCT01134042GlaxoSmithKline587
已完成
3 期
Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent AsthmaticsAsthmaNCT01165138GlaxoSmithKline612
已完成
3 期
An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in AsthmaAsthmaNCT01706198GlaxoSmithKline4,233